An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,250

Participants

Timeline

Start Date

February 28, 2006

Conditions
Ankylosing Spondylitis
Interventions
DRUG

adalimumab (Humira)

Trial Locations (205)

7

Dublin

3010

Bern

3600

Genk

5504

Haugesund

6000

Charleroi

7600

Levanger

8000

Bruges

8063

Zurich

8091

Zurich

8400

Ostend

9038

Tromsø

9300

Aalst

9320

Erembodegem

10117

Berlin

11521

Athens

11527

Athens

12200

Berlin

13055

Berlin

13125

Berlin

13285

Marseille

13385

Marseille

13616

Aix-en-Provence

14033

Caen

15006

A Coruña

17033

Neubrandenburg

18059

Rostock

20521

Turku

21033

Dijon

21075

Hamburg

22023

Saint-Brieuc

22147

Hamburg

24116

Kiel

24349

Damp

24576

Bad Bramstedt

25030

Besançon

26500

Pátrai

27404

Zeven

28007

Madrid

28034

Madrid

28035

Madrid

28041

Madrid

28880

Madrid

29609

Brest

30625

Hanover

31008

Pamplona

31059

Toulouse

33012

Asturias

33076

Bordeaux

33505

Libourne

34295

Montpellier

35016

Las Palmas de Gran Canaria

35020

Las Palmas de Gran Canaria

35203

Rennes

37044

Tours

37075

Göttingen

38043

Grenoble

38640

Goslar

39245

Vogelsang/Gommern

39261

Zerbst

40225

Düsseldorf

41110

Larissa

42055

Saint-Etienne

42100

Reggio Emilia

44035

Nantes

44652

Herne

45032

Orléans

45100

Kouvola

45500

Ioannina

46005

Cahors

46017

Valencia

47010

Valladolid

47055

Duisburg

48013

Vizcaya

48324

Sendenhorst

48903

Barakaldo

49033

Angers

50009

Zaragoza

50139

Florence

50924

Cologne

51092

Reims

54511

Vandœuvre-lès-Nancy

54636

Thessaloniki

54642

Thessaloniki

55134

Thessaloniki

56403

Thessaloniki

59037

Lille

59322

Valenciennes

59462

Lomme

60528

Frankfurt

62608

Berck

62806

Liévin

63003

Clermont-Ferrand

64046

Pau

67098

Strasbourg

68070

Mulhouse

69310

Lyon

69365

Lyon

69437

Lyon

70178

Stuttgart

70372

Stuttgart

72037

Le Mans

72076

Tübingen

73106

Aix-les-Bains

75012

Paris

75014

Paris

75475

Paris

75651

Paris

76290

Montivilliers

78054

Villingen

79106

Freiburg im Breisgau

80054

Amiens

80131

Napoli

80639

München

81541

München

83043

Bad

85100

Potenza

86021

Poitiers

87042

Limoges

90016

Belfort

90127

Palermo

91054

Erlangen

91108

Corbeil-Essonnes

92100

Boulogne-Billancourt

93042

Regensburg

94010

Créteil

94275

Le Kremlin-Bicêtre

99096

Erfurt

A-8020

Graz

A-8036

Graz

A-6020

Innsbruck

A-1090

Vienna

A-1100

Vienna

B-9111

Belsele

B-9000

Ghent

B-3500

Hasselt

DK-2000

Frederiksberg

DK-7500

Holstebro

DK-6000

Kolding

DK-8900

Randers

DK-8600

Silkeborg

00280

Helsinki

05800

Hyvinkää

06202

Nice

D-48455

Bad Bentheim

D-61231

Bad Nauheim

D-14109

Berlin

D-09130

Chemnitz

03048

Cottbus

01307

Dresden

D-01067

Dresden

D-22081

Hamburg

D-69115

Heidelberg

D-31134

Hildesheim

D-65719

Hofheim

02977

Hoyerswerda

D-07747

Jena

04103

Leipzig

D-49074

Osnabrück

D-82152

Planegg

D-40882

Ratingen

D-97070

Würzburg

Unknown

Athens

Heraklion

Cork

09042

Monserrato

00161

Roma

1782 GZ

Den Helder

7511 JX

Enschede

4382 EE

Flushing

8934 AD

Leeuwarden

8011 JW

Zwolle

N-2609

Lillehammer

N-7006

Trondheim

03203

Alicante

08003

Barcelona

08035

Barcelona

08208

Barcelona

08221

Barcelona

08304

Barcelona

09005

Burgos

01009

Vitoria-Gasteiz

SE-631 88

Eskilstuna

SE- 701 85

Örebro

SE-831 83

Östersund

SE-351 85

Vaxjo

AB25 2ZN

Aberdeen

BA1 1RL

Avon

B29 6JD

Birmingham

CB2 2QQ

Cambridge

M6 8HD

Greater Manchester

HA1 3UJ

Harrow

HD3 3EA

Huddersfield

LS7 4SA

Leeds

L9 7AL

Liverpool

SE1 9RT

London

SE5 9PJ

London

SW10 9NH

London

CH49 5PE

Merseyside

NE7 7DN

Newcastle upon Tyne

OX3 7LD

Oxford

PO6 3LY

Portsmouth

S10 2JF

Sheffield

SO16 6YD

Southampton

TR1 3LJ

Truro

WN6 9EP

Wigan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00478660 - An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) | Biotech Hunter | Biotech Hunter